NEW YORK, March 7 /PRNewswire/ -- On March 6, Geoffrey Henson, Chief Executive Officer for FermaVir Pharmaceuticals, Inc. updated the investment community in an exclusive interview with www.wallst.net . Topics covered in the interview include an overview of the Company and the markets it serves, recent press releases, current capitalization, upcoming strategic and financial milestones.
To hear the interview in its entirety, visit www.wallst.net , and click on “Interviews.” The interview can be accessed either by locating the company’s ticker symbol under the appropriate exchange on the left-hand column of the “Interviews” section of the site, or by entering the company’s ticker symbol in the Search Archive window.
About FermaVir Pharmaceuticals, Inc.:
FermaVir Pharmaceuticals, Inc. is an emerging biotechnology company positioned for rapid growth by developing important antiviral drugs and other treatments in underserved segments of the pharmaceutical development marketplace. The Company’s Intellectual Property portfolio includes a number of patent applications and a worldwide exclusive license for potential new drug treatments of infectious diseases. Among FermaVir’s lead drug candidates is a breakthrough antiviral treatment that has demonstrated powerful inhibitory activity and may have potential therapeutic benefit for the treatment of shingles, also known as herpes zoster. FermaVir’s proprietary compound, FV-100, is believed to be 10,000 times more potent than currently approved shingles drug treatments. FermaVir is also developing compounds that could provide the first improved effective treatment in years for Cytomegalovirus (CMV) infection, a currently incurable viral disease from the herpes family that can threaten eyesight as well as cause severe morbidity and mortality.
About WallSt.net:
www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. The website is a leading provider of financial news, media, tools and community-driven applications for investors. www.wallst.net offers visitors free membership to its in-depth executive interviews, exclusive editorial content, breaking news, and several proprietary applications. In addition to its website, WallStreet Direct organizes investor conferences, publishes a newspaper, and provides multimedia advertising solutions to small and mid-sized publicly traded companies. We are expecting to receive two hundred eighty dollars from FermaVir Pharmaceuticals, Inc. for the dissemination of this press release. For a complete list of our advertisers, and advertising relationships, visit http://www.wallst.net/disclaimer/disclaimer.asp .
(Logo: http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGO)
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comWallStreet Direct, Inc.
CONTACT: Nick Iyer of Digital Wall Street, Inc., +1-800-4-WALL-ST
Web site: http://www.wallst.net/
